The DOI matches its Crossref record; 231 of the 256 references it cites were found in a registry or an index.
Rapamycin: An anti-cancer immunosuppressant?
Abstract
Rapamycin and its derivatives are promising therapeutic agents with both immunosuppressant and anti-tumor properties. These rapamycin actions are mediated through the specific inhibition of the mTOR protein kinase. mTOR serves as part of an evolutionarily conserved signaling pathway that controls the cell cycle in response to changing nutrient levels. The mTOR signaling network contains a number of tumor suppressor genes including PTEN, LKB1, TSC1, and TSC2, and a number of proto-oncogenes including PI3K, Akt, and eIF4E, and mTOR signaling is constitutively activated in many tumor types. These observations point to mTOR as an ideal target for anti-cancer agents and suggest that rapamycin is such an agent. In fact, early preclinical and clinical studies indicate that rapamycin derivatives have efficacy as anti-tumor agents both alone, and when combined with other modes of therapy. Rapamycin appears to inhibit tumor growth by halting tumor cell proliferation, inducing tumor cell apoptosis, and suppressing tumor angiogenesis. Rapamycin immunosuppressant actions result from the inhibition of T and B cell proliferation through the same mechanisms that rapamycin blocks cancer cell proliferation. Therefore, one might think that rapamycin-induced immunosuppression would be detrimental to the use of rapamycin as an anti-cancer agent. To the contrary, rapamycin decreases the frequency of tumor formation that occurs in organ transplant experiments when combined with the widely used immunosuppressant cyclosporine compared with the tumor incidence observed when cyclosporine is used alone. The available evidence indicates that with respect to tumor growth, rapamycin anti-cancer activities are dominant over rapamycin immunosuppressant effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sirolimus, which is an mTOR inhibitor, possesses antitumor activity 171”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [171]
Citations
Cites
1 retracted
Items 201–231 of 231
Atypical protein kinase Cλ binds and regulates p70 S6 kinase
Akimoto, K., Nakaya, M., Yamanaka, T., TANAKA, J., MATSUDA, S.-I., Qing-Ping, W. E. N. G., Avruch, J., & Ohno, S. (1998) · Biochemical Journal · doi:10.1042/bj3350417 · Cited by 74
Role of phospholipase D1 in the regulation of mTOR activity by lysophosphatidic acid
Kam, Y., & Exton, J. H. (2004) · The FASEB Journal · doi:10.1096/fj.03-0731com · Cited by 72
Rapamycin induces Smad activity in prostate cancer cell lines
van der Poel, H. G., Hanrahan, C. F., Zhong, H., & Simons, J. W. (2003) · Urological Research · doi:10.1007/s00240-002-0282-1 · Cited by 70
Withers, D. J., Ouwens, D. M., NAVÉ, B. T., van der Zon, G. C. M., Alarcón, C. M., Cardenas, M. E., Heitman, J., Maassen, J. A., & Shepherd, P. R. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7878 · Cited by 69
Germline mutations of the LKB1 (STK11) gene in Peutz-Jeghers patients
Wang, Z.-J., Churchman, M., Avizienyte, E., McKeown, C., Davies, S. J., Evans, D. G., Ferguson, A., Ellis, I., Xu, W.-H., Yan, Z.-Y., et al. (1999) · Journal of Medical Genetics · doi:10.1136/jmg.36.5.365 · Cited by 68
Cyclin D1 Associates with the TBP-associated factor TAFII250 to regulate Sp1-mediated transcription
Adnane, J., Shao, Z., & Robbins, P. D. (1999) · Oncogene · doi:10.1038/sj.onc.1202297 · Cited by 66
Miyagi, Y., Sugiyama, A., Asai, A., Okazaki, T., Kuchino, Y., & Kerr, S. J. (1995) · Cancer Letters · doi:10.1016/0304-3835(95)03737-h · Cited by 62
Kim, S. K., Su, L.-K., Oh, Y. W., Kemp, B. L., Hong, W. K., & Mao, L. (1998) · Oncogene · doi:10.1038/sj.onc.1201512 · Cited by 61
Fukazawa, H., & Uehara, Y. (2000) · PubMed · Cited by 58
Zezula, J., Sexl, V., Hutter, C., Karel, A., Schütz, W., & Freissmuth, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.47.29967 · Cited by 52
Cdc42 Promotes G1 Progression through p70 S6 Kinase-mediated Induction of Cyclin E Expression
Chou, M. M., Robens, J., & Gupta, M. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305246200 · Cited by 51
l-Asparaginase Inhibits the Rapamycin-Targeted Signaling Pathway
Iiboshi, Y., Papst, P. J., Hunger, S. P., & Terada, N. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0920 · Cited by 48
Feuerstein, N., Huang, D., & Prystowsky, M. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.16.9454 · Cited by 47
Law, B. K., Nørgaard, P. H., Gnudi, L., Kahn, B. B., Poulson, H. S., & Moses, H. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.8.4743 · Cited by 46
Law, B. K., Nørgaard, P. H., & Moses, H. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.10796 · Cited by 45
Susa, M., Vulević, D., Lane, H. A., & Thomas, G. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50514-2 · Cited by 44
The zinc finger protein GLI induces cellular sensitivity to the mTOR inhibitor rapamycin.
Louro, I. D., McKie-Bell, P., Gosnell, H., Brindley, B. C., Bucy, R. P., & Ruppert, J. M. (1999) · PubMed · Cited by 44
Involvement of the Akt/mTOR pathway on EGF‐induced cell transformation
Nomura, M., He, Z., Koyama, I., Ma, W., Miyamoto, K., & Dong, Z. (2003) · Molecular Carcinogenesis · doi:10.1002/mc.10140 · Cited by 44
Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma.
Alimov, A. A., Li, C., Gizatullin, R. Z., Fredriksson, V., Sundelin, B., Klein, G., Zabarovsky, E. R., & Bergerheim, U. S. R. (1999) · PubMed · Cited by 40
Withers, D. J., Seufferlein, T. T. W., Mann, D. J., García, B., Jones, N. C., & Rozengurt, E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2509 · Cited by 39
Bared essentials of CDK2 and cyclin E
Roberts, J. M., & Sherr, C. J. (2003) · Nature Genetics · doi:10.1038/ng1234 · Cited by 38
Bodner, S. M., Naeve, C. W., Rakestraw, K. M., Jones, B. G., Valentine, V. A., Valentine, M. B., Luthardt, F. W., Willman, C. L., Raimondi, S. C., Downing, J. R., et al. (1999) · Gene · doi:10.1016/s0378-1119(98)00591-5 · Cited by 38
Ca2+‐ and phospholipase D‐dependent and ‐independent pathways activate mTOR signaling
Ballou, L. M., Jiang, Y.-P., Du, G., Frohman, M. A., & Lin, R. Z. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00816-0 · Cited by 37
Gaben, A., Saucier, C., Bedin, M., Barbu, V., & Mešter, J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11521 · Cited by 35
Kidney transplantation without calcineurin inhibitors using sirolimus
Stegall, M. D., Larson, T. S., Prieto, M., Gloor, J. M., Textor, S. C., Nyberg, S. L., Sterioff, S., Ishitani, M., Griffin, M. D., Kremers, W. K., et al. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00226-4 · Cited by 34
IMMUNOSUPPRESSIVE PROPERTIES OF FK-506 AND RAPAMYCIN
Thomson, A. W., & Woo, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90616-8 · Cited by 33
Minimizing calcineurin inhibitor drugs in renal transplantation
Flechner, S. M. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00218-5 · Cited by 30
Synergism of RAD and Cyclosporin A in Prevention of Acute Rat Corneal Allograft Rejection
Reis, A., Megahed, M., Reinhard, T., Godehardt, E. A. J., Braunstein, C., & Sundmacher, R. (2002) · Cornea · doi:10.1097/00003226-200201000-00017 · Cited by 23
Collier, S. J. (1989) · Current Opinion in Immunology · doi:10.1016/0952-7915(89)90169-6 · Cited by 21
Chen, Y., Knudsen, E. S., & Wang, J. (1996) · PubMed · Cited by 18
Flagged first, then by citations
25 of the 256 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Smith, 1990, Translation initiation factors induce DNA synthesis and transform NIH 3T3 cells, New Biol, 2, 648
Cited by
Sorted by citations
LKB1-Dependent Signaling Pathways
Alessi, D. R., Sakamoto, K., & Bayascas, J. R. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142702 · Cited by 805
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
Franz, D. N., Leonard, J. M., Tudor, C., Chuck, G., Caré, M. M., Sethuraman, G., Dinopoulos, A., Thomas, G., & Crone, K. R. (2006) · Annals of Neurology · doi:10.1002/ana.20784 · Cited by 609
A Review of the Microbial Production of Bioactive Natural Products and Biologics
Pham, J. V., Yilma, M. A., Feliz, A., Majid, M. T., Maffetone, N., Walker, J. R., Kim, E., Cho, H. J., Reynolds, J. M., Song, M., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01404 · Cited by 570
Wang, X., Pan, C., Gong, J., Liu, X., & Li, H. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00690 · Cited by 300
Cancer in the Transplant RecipientPreprint
Chapman, J. R., Webster, A. C., & Wong, G. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015677 · Cited by 277
Metadata
- Authors
- Law, B. K.
- Affiliations
- University of Florida (US)
- Corresponding author
- Law, Brian K.
- ORCID
- Law, Brian K.
- Venue
- Critical Reviews in Oncology/Hematology
- Publisher
- Elsevier BV
- Published
- 2005-10
- Volume
- 56
- Issue
- 1
- Pages
- 47-60
- ISSN
- 1040-8428 (ISSN-L)
- OpenAlex
- W2764507256
- Cited by
- 252
- References
- 256
- Citations by year
- 2026: 1 · 2025: 12 · 2024: 14 · 2023: 16 · 2022: 14 · 2021: 9 · 2020: 8 · 2019: 18 · 2018: 9 · 2017: 15 · 2016: 9 · 2015: 10 · 2014: 23 · 2013: 16 · 2012: 10
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Critical Reviews in Oncology/Hematology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- rapamycin, mTOR signaling, immunosuppression, anticancer activity, tumor angiogenesis, apoptosis, tumor cell proliferation, cyclosporine, organ transplantation, tumor suppression, PI3K/Akt signaling, TSC1/TSC2, PTEN, LKB1, eIF4E
- MeSH terms
- Animals, Antineoplastic Agents, Cell Cycle, Drug Synergism, Humans, Immunosuppressive Agents, Neoplasms, Neovascularization, Pathologic, Protein Kinases, Drug Design, Signal Transduction, Molecular Chaperones, Sirolimus, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
